Regulome-guided drug repurposing identifies a losartan–tacrolimus combination for ulcerative colitis: from in silico ceRNA networks to exploratory in vivo outcomes
Year: 2026
Type: article
Abstract: Introduction Ulcerative colitis (UC) is a chronic inflammatory condition influenced by genes, the immune system, and the environment. Many patients experience treatment failure, highlighting the need for novel strategies such as drug repurposing. In this study, we aim to evaluate the effects of losartan, an angiotensin receptor blocker, and tacrolimus, a calcineurin inhibitor, individually and in combination, for the exploratory study of their therapeutic effect in the treatment of UC. Method Computational analyses using miRDB, DisGeNET, RNAcentral, TargetScan, and Reactome were used to identify shared candidate genes, predicted ceRNA interactions (lncRNA/piRNA–miRNA–mRNA axes), and enriched pathways that are potentially relevant to UC. Selected molecular components identified within candidate ceRNA axes were subsequently assessed in a rat model of dextran sulfate sodium (DSS)-induced colitis treated for 3 weeks with losartan at a dose of 10 mg/kg/day, tacrolimus at 0.5 mg/kg/day, or a combination of both drugs. Clinical, hematological, qualitative histopathological, and molecular outcomes were examined. Molecular and biochemical endpoints were based on three independent animals per group. Results The computational analysis identified nine key shared genes, including STAT3, TNF-α, and IL-6, which are targets of miRNAs implicated in UC. In the animal model, combination therapy was associated with reductions in the measured abundance of selected inflammatory markers and partial restoration of miR-124-3p and miR-16 expression, compared to the individual drugs. Qualitative examination of representative colonic sections indicated improved tissue organization in treated groups (particularly in combination therapy) and in further restorations of hematological parameters. Conclusion The losartan–tacrolimus combination was associated with changes in selected inflammatory, molecular, hematological, and morphological outcomes in this exploratory DSS-induced colitis study. Together with the predicted ceRNA associations, these observed changes illustrate the potential of regulome-guided network analysis to prioritize candidate drug combinations for further investigation in complex inflammatory disorders.
Source: Frontiers in Pharmacology
Authors: Rofayda Ihab(Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing), Mona M. Saber(Conceptualization, Formal analysis, Methodology, Resources, Visualization, Writing – original draft, Writing – review & editing), Ahmed S. Fouad(Conceptualization, Investigation, Writing – original draft, Writing – review & editing), Ahmed A. El-Sherif(Conceptualization, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review & editing), Achraf El Allali, Mohamed A. M. Atia(Conceptualization, Formal analysis, Project administration, Resources, Supervision, Visualization, Writing – original draft, Writing – review & editing)
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Keywords: ulcerative colitis, drug repurposing, losartan, tacrolimus, combination therapy, competing endogenous RNA network, microRNA, long non-coding RNA, DSS-induced colitis, rat model, STAT3, TNF-α, interleukin-6, miR-124-3p, miR-16, inflammatory bowel disease, hematological parameters, colonic histopathology
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236742043
